Fig. 1 · Structure

Documents & Downloads

Telaprevir (VX-950)

Cat. No. A10902 CAS 402957-28-2

HCV NS3-4A protease inhibitor

Telaprevir (VX-950) is known as protease inhibitors that inhibits the hepatitis C virus NS3.4A serine protease.

In Stock

Publications for Telaprevir

9 publications citing this product

  1. Mahim Khan, .et al. , BMC Complement Med Ther, 2022, Apr 2;22(1):98 PMID: 35366855
  2. Adita Ayu Permanasari, .et al. , BMC Complement Med Ther, 2021, Oct 12;21(1):260 PMID: 34641875
  3. Che C Colpitts, .et al. , eLife, 2020, 9: e52237 PMID: 32539931
  4. TS Wahyuni, .et al. , Southeast Asian J Trop Med public health, 2020, 51(1)
  5. Stefan Bittmann, .et al. , J Regen Biol Med, 2020, 2(2):1-3
  6. Wahyuni TS, .et al. , J Basic Clin Physiol Pharmacol, 2019, Dec 14 PMID: 31837259
  7. Jacobs CL, .et al. , Nat Methods, 2018, Jul;15(7):523-526 PMID: 29967496
  8. Apriyanto DR, .et al. , Jpn J Infect Dis, 2016, May 20;69(3):213-20 PMID: 26255732
  9. Mizuki Yamamoto, .et al. , Antimicrob Agents Chemother, 2016, Nov; 60(11): 6532-6539 PMID: 27550352

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Telaprevir (VX-950) is an α-ketoamide inhibitor that forms a covalent, reversible complex with HCV NS3-4A protease. For the genotype 1a H-strain enzyme, the reported steady-state Ki* was 7 nM and the inhibited-complex dissociation half-life was 58 min. These are enzyme-kinetics endpoints, rather than cellular IC50 values. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
HCV NS3-4A serine protease 0.35 μM

Cellular Effect

Cell Line Activity Value Description Reference
Hepatocyte CC50 90 μM Cytotoxicity against human hepatocytes by MTT assay [PMID: 19345581]
Huh-5-2 CC50 > 33 μM Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay [PMID: 18625766]
Huh-5-2 CC50 > 74 μM Cytostatic activity against human Huh5-2 cells assessed as decrease in cell proliferation after 3 days by MTS method 10.1039/C1MD00227A
Huh-5-2 EC50 1 μM Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay [PMID: 18625766]
Huh-5-2 EC50 235 nM Antiviral activity against Hepatitis C virus genotype 1b I389luc-ubi-neo/NS3-3'/5.1 subgenomic replicon infected in human Huh5-2 cells after 4 days by luciferase assay 10.1039/C1MD00227A
Huh-5-2 CC50 47 μM Cytotoxicity against human HuH5.2 cells assessed as reduction in cell viability after 72 hrs by MTS assay [PMID: 27810598]
Huh-5-2 CC50 47 μM Cytotoxicity against human HuH5.2 cells assessed as reduction in metabolic activity after 72 hrs by MTS assay [PMID: 27474921]
Huh-5-2 CC50 47 μM Cytotoxicity against human Huh5-2 cells after 72 hrs by MTS assay [PMID: 25617695]
Huh-7 IC50 < 0.14 μM Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis [PMID: 23999140]
Huh-7 CC50 > 20 μM Cytotoxicity against human HuH7 cells after 3 days by tetrazolium dye method [PMID: 26483202]
Huh-7 CC50 > 20 μM Cytotoxicity against human HuH7 cells expressing luciferase reporter gene after 3 days by WST-8 assay [PMID: 24900815]
Huh-7 EC50 > 30 μM Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay [PMID: 17938182]
Huh-7 EC50 > 30 μM Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay [PMID: 17938182]
Huh-7 EC50 > 30 μM Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/A156T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay [PMID: 17938182]
Huh-7 EC50 0.129 μM Antiviral activity against chimeric HCV FL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as reduction of intracellular viral RNA level after 72 hrs by RT-PCR assay [PMID: 26551513]
Huh-7 EC50 0.36 μM Antiviral activity against HCV genotype 1b infected in human HuH7 cells after 3 days by luciferase reporter gene assay [PMID: 26483202]
Huh-7 EC50 0.45 μM Antiviral activity against HCV1b infected in human HuH7 cells expressing luciferase reporter gene assessed as reduction of luciferase activity after 3 days [PMID: 24900815]
Huh-7 EC50 0.49 μM Antiviral activity against wild type Con1-mADE HCV replicon in human HuH7 cells after 48 hrs by RNA replicon assay [PMID: 17938182]
Huh-7 IC50 0.49 μM Antiviral activity against wild type HCV 1b Con1 in human Huh7 cells after 48 hrs by replicon cell assay [PMID: 17556358]

19 records · Scroll to view more

Telaprevir (VX-950) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Telaprevir (VX-950) from 2 published references. In vitro models include purified HCV H-strain NS3 protease domain with KK4A cofactor peptide; Con1 genotype 1b subgenomic HCV replicon cells in Huh-7 background.

Telaprevir (VX-950) In Vitro Studies

In Con1 genotype 1b subgenomic replicon cells, 48-h VX-950 exposure gave an HCV RNA IC50 of 0.354 ± 0.035 μM and IC90 of 0.830 ± 0.190 μM in 2% FBS (mean ± SD, three independent experiments). The matched viability CC50 was 83 ± 27 μM. These model-specific assay values do not establish clinical efficacy. [2]

Human serum reduced the apparent cellular potency of VX-950: the 48-h RNA IC50 rose from 0.33 μM without added human serum to 3.45 μM with 40% human serum. Serum composition therefore matters when comparing potency values across assay conditions. [2]

Reversible, slow-dissociating inhibition of genotype 1a NS3-4A

Biochemical assay · Purified HCV H-strain (genotype 1a) NS3 protease domain with KK4A cofactor peptide [1]

VX-950 formed a covalent, reversible inhibited complex. Steady-state binding and dissociation were measured separately within the enzyme-kinetics characterization.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Steady-state inhibition of H-strain genotype 1a NS3-4AKi* 7 nM[1]
Dissociation half-life of the inhibited enzyme complext1/2 58 min[1]

Literature-Reported Treatment Conditions

Exposure duration
Steady-state rates at 4 h; dissociation followed over a 4-h window
Method
Fluorescent peptide-cleavage kinetics; Morrison tight-binding fit for Ki* and dilution-based recovery of activity for dissociation
Vehicle
2% DMSO
Reported limits
No variance or replicate count reported for the quoted Ki* and complex half-life. Ki* is not an IC50.
Methods and source locations

Compound reported in the paper: Telaprevir (VX-950); Compound label in the paper: VX-950

Applies to the named compound and the genotype 1a enzyme assay; does not establish universal genotype potency.

Materials; Figure 1A-B; Table 1 identity/footnote; fluorescence cleavage methods; Results: VX-950 forms a tight, long-lived complex

Steady-state inhibition of H-strain genotype 1a NS3-4A: Fluorescent peptide cleavage; steady-state rate at 4 h; Morrison equation; DMSO control — Fluorescence peptide cleavage methods; Results: VX-950 forms a tight, long-lived complex, first paragraph

Dissociation half-life of the inhibited enzyme complex: Recovery of peptide-cleavage activity after dilution; no-inhibitor DMSO control — Fluorescence peptide cleavage methods; Results: VX-950 forms a tight, long-lived complex, first paragraph

Acute replicon inhibition with matched cytotoxicity evaluation

Cell-based study · Con1 genotype 1b subgenomic HCV replicon cells in Huh-7 background [2]

VX-950 reduced cellular HCV RNA in a time-dependent manner. Three independent 48-h experiments supplied the RNA inhibition estimates. The accompanying MTS viability CC50 was much higher; its independent-experiment count is not separately stated. Figure 2 is a representative time-course concentration series, not the three-experiment aggregate.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reduction in cellular HCV RNAIC50 (mean ± SD) 0.354 ± 0.035 μM[2]
Reduction in cellular HCV RNAIC90 (mean ± SD) 0.830 ± 0.190 μM[2]
Loss of replicon-cell viabilityCC50 (mean ± SD) 83 ± 27 μM[2]

Literature-Reported Treatment Conditions

Exposure duration
48 h for aggregate IC50, IC90 and CC50
Method
Quantitative RT-PCR RNA endpoint with parallel MTS cell viability assay; 2% FBS
Vehicle
0.5% DMSO (no-compound control)
Reported limits
Dose range for the aggregate three-experiment fit is not enumerated with those aggregate estimates; do not substitute the representative Figure 2 range.
Methods and source locations

Compound reported in the paper: Telaprevir (VX-950); Compound label in the paper: VX-950

Cellular RNA inhibition and viability endpoints in a subgenomic model; no clinical efficacy inference.

Materials; Determination of anti-HCV activity and cytotoxicity; first Results subsection; Figure 2 and caption

Reduction in cellular HCV RNA: 48-h assay in 2% FBS; 3 independent experiments; RNA by quantitative RT-PCR, viability by MTS — Results: VX-950 reduced HCV RNA levels in replicon cells in a time- and dose-dependent manner, first paragraph

Reduction in cellular HCV RNA: 48-h assay in 2% FBS; 3 independent experiments; RNA by quantitative RT-PCR, viability by MTS — Results: VX-950 reduced HCV RNA levels in replicon cells in a time- and dose-dependent manner, first paragraph

Loss of replicon-cell viability: 48-h MTS viability assay in 2% FBS; mean ± SD; independent-experiment count for CC50 not separately stated — Results: VX-950 reduced HCV RNA levels in replicon cells in a time- and dose-dependent manner, first paragraph

Human-serum-dependent loss of apparent cellular potency

Cell-based study · Con1 genotype 1b subgenomic HCV replicon cells with 0%, 10%, 20% or 40% added human serum [2]

Increasing human serum shifted the 48-h RNA inhibition endpoints upward. No-compound controls were included at the serum conditions; the authors report that serum alone had little, if any, effect on RNA levels. This experiment limits extrapolation from low-serum potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
48-h RNA inhibition IC50 at 0%, 10%, 20%, 40% human serumIC50 0.33, 0.88, 1.40, 3.45 μM, respectively[2]
48-h RNA inhibition IC90 at 0%, 10%, 20%, 40% human serumIC90 0.79, 1.37, 2.52, 4.76 μM, respectively[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.03, 0.1, 0.3, 1, 3 or 10 μM
Exposure duration
48 h
Method
Quantitative RT-PCR; comparison across human-serum conditions
Vehicle
0.5% DMSO control
Reported limits
No replicate count or uncertainty supplied in Table 1. Serum CC50 entries are not adopted: the footnote lists an antiviral concentration series ending at 10 μM, while cytotoxicity bounds extend above that range; a separate toxicity series is not specified there.
Methods and source locations

Compound reported in the paper: Telaprevir (VX-950); Compound label in the paper: VX-950

Potency shifts in this cellular assay only; no human-dose prediction.

Effect of human serum on anti-HCV activity of VX-950; Table 1 and footnote

48-h RNA inhibition IC50 at 0%, 10%, 20%, 40% human serum: 48-h quantitative RT-PCR assay; Table 1 supplies no error estimates — Table 1, IC50 column and footnote a

48-h RNA inhibition IC90 at 0%, 10%, 20%, 40% human serum: 48-h quantitative RT-PCR assay; Table 1 supplies no error estimates — Table 1, IC90 column and footnote a

Telaprevir (VX-950) In Vivo Studies

After a single oral 30 mg/kg VX-950 dose in male Fisher rats, the reported 0-8 h liver/plasma AUC ratio was 35.1. This distribution result used an achiral assay that combined VX-950 and its P1 R-diastereomer, with liver density assumed to be 1 g/mL. It does not establish selective telaprevir exposure or antiviral efficacy. [1]

Rat liver and plasma distribution after a single oral dose

Animal study · Male Fisher rats (strain spelling as reported); 3 animals per sampling group [1]

After oral VX-950, liver exposure exceeded plasma exposure over 0-8 h. The achiral assay measured VX-950 together with its P1 R-diastereomer; this is distribution evidence, not an antiviral efficacy experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Liver exposure, 0-8 h; paper assumes liver density 1 g/mLAUC0-8 (mean ± SD) 78.5 ± 40.0 μg·h/mL[1]
Plasma exposure, 0-8 hAUC0-8 (mean ± SD) 2.23 ± 1.53 μg·h/mL[1]
Liver/plasma exposure ratio over 0-8 hAUC0-8 ratio 35.1[1]

Conditions shared by the study groups

Route
Oral
Frequency
Once
Treatment course
Single dose; exposure sampled through 8 h
Vehicle
Propylene glycol
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Single oral VX-950
30 mg/kg
Predose sampling group; plasma provides the within-design distribution comparatorReported 0-8 h liver/plasma AUC ratio 35.1; assay combines VX-950 and its P1 R-diastereomer.[1]
Single oral VX-950
Model: Male Fisher rats; 3 per sampling group
Reported limits: No antiviral endpoint or vehicle-only efficacy control in this distribution design.
Methods and source locations

Compound reported in the paper: Telaprevir (VX-950); Compound label in the paper: VX-950

Supports combined-analyte distribution after dosing VX-950, not selective S-diastereomer exposure or efficacy.

Evaluation of liver-to-plasma ratio of VX-950 in rats; Pharmacokinetics Results; Table 4 and footnotes

Liver exposure, 0-8 h; paper assumes liver density 1 g/mL: Achiral LC/MS/MS; Table 4 reports averages ± SD, 3 animals — Table 4, Liver row, AUC0-8 column and footnotes a-b

Plasma exposure, 0-8 h: Achiral LC/MS/MS; Table 4 reports averages ± SD, 3 animals — Table 4, Plasma row, AUC0-8 column and footnote a

Liver/plasma exposure ratio over 0-8 h: Reported ratio, with assumed liver density 1 g/mL; no variance supplied — Table 4, Liver/plasma ratio row, AUC0-8 column and footnote b

Single oral VX-950 · Evaluation of liver-to-plasma ratio methods; Table 4 and footnotes

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 402957-28-2
Applications HCV NS3-4A protease inhibitor
Formula C36H53N7O6
Molecular Weight 679.9
Synonyms VX950; Incivek; Incivo
SMILES
CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 131 mg/mL (192.69 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Telaprevir (VX-950) Research References

  1. [1] Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrobial Agents and Chemotherapy (2006). PMID: 16495249 DOI: 10.1128/aac.50.3.899-909.2006 Source material
  2. [2] Lin K, Perni RB, Kwong AD, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrobial Agents and Chemotherapy (2006). PMID: 16641454 DOI: 10.1128/aac.50.5.1813-1822.2006 Source material

Publications

9 publications citing this product

  1. Mahim Khan, .et al. , BMC Complement Med Ther, 2022, Apr 2;22(1):98 PMID: 35366855
  2. Adita Ayu Permanasari, .et al. , BMC Complement Med Ther, 2021, Oct 12;21(1):260 PMID: 34641875
  3. Che C Colpitts, .et al. , eLife, 2020, 9: e52237 PMID: 32539931
  4. TS Wahyuni, .et al. , Southeast Asian J Trop Med public health, 2020, 51(1)
  5. Stefan Bittmann, .et al. , J Regen Biol Med, 2020, 2(2):1-3
  6. Wahyuni TS, .et al. , J Basic Clin Physiol Pharmacol, 2019, Dec 14 PMID: 31837259
  7. Jacobs CL, .et al. , Nat Methods, 2018, Jul;15(7):523-526 PMID: 29967496
  8. Apriyanto DR, .et al. , Jpn J Infect Dis, 2016, May 20;69(3):213-20 PMID: 26255732
  9. Mizuki Yamamoto, .et al. , Antimicrob Agents Chemother, 2016, Nov; 60(11): 6532-6539 PMID: 27550352

Added to your cart

View Cart Checkout
Loading...